Physician profile
Patrick M Woodward
NPI 1447204557
$12,569.29
in general payments reported to CMS, 2019-2025
81 companies · $1,442 in 2025
The $1,442 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,120 · 2020: $2,210 · 2021: $2,125 · 2022: $1,688 · 2023: $1,584 · 2024: $1,400 · 2025: $1,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,425.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,763.54 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,605.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $871.81 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $699.13 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $671.95 | 2019-2024 | Farxiga |
| Glaxosmithkline, LLC. | $636.09 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $630.60 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $544.04 | 2019-2024 | Jardiance, Tradjenta |
| Lilly USA, LLC | $499.09 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $495.28 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Merck Sharp & Dohme LLC | $446.16 | 2019-2025 | Belsomra, Steglatro, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $217.10 | 2019-2025 | Trintellix |
| Astellas Pharma US INC | $162.63 | 2019-2021 | |
| Ethicon US, LLC | $152.81 | 2025 | Linx Reflux Management System |
| Esperion Therapeutics, INC. | $150.25 | 2020-2025 | Nexletol |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Woodward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.